ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Summary

This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of ICP-022 versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.

Timeline

Start

2021-01-08

Primary completion

2024-12-30

Completion

2025-06-30

Publications

• Li F, Zhou K, Xu W, Cui G, Yi S, Jin J, Zhu Z, He A, Mi J, Xia Z, Huang X, Zhou X, Yu W, Guo J, Zeng Q, Huang S, Shuang Y, Peng H, Qiu L, Xu B, Li Y, Yang Y, Zhou F, Wang Y, Liu L, Ren J, Li Y, Yang W, Gu J, Ouyang G, Hua L, Zhang J, Xiao Q, Wang S, Zhang Q, Liu J, Ding K, Zhang L, Zeng Y, Li Z, Wen Q, Gao K, Yang H, Jiang Y, Chen Y, Li Z, Tang X, Wang W, Zhao R, Qiu L, Li J. Orelabrutinib versus chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial. Signal Transduct Target Ther. 2026 Jul 6;11(1):261. doi: 10.1038/s41392-026-02818-x.

Drugs

Indications